Werewolf TherapeuticsHOWL
Market Cap: $88.3M
About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Employees: 45
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
4,267% more call options, than puts
Call options by funds: $131K | Put options by funds: $3K
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
15% more funds holding
Funds holding: 61 [Q1] → 70 (+9) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
1.33% less ownership
Funds ownership: 75.51% [Q1] → 74.17% (-1.33%) [Q2]
62% less capital invested
Capital invested by funds: $209M [Q1] → $78.7M (-$130M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Andres Maldonado 42% 1-year accuracy 16 / 38 met price target | 643%upside $15 | Buy Reiterated | 2 Jul 2024 |
JMP Securities Reni Benjamin 44% 1-year accuracy 14 / 32 met price target | 494%upside $12 | Market Outperform Reiterated | 26 Jun 2024 |
HC Wainwright & Co. Andres Maldonado 42% 1-year accuracy 16 / 38 met price target | 643%upside $15 | Buy Reiterated | 26 Jun 2024 |